Haoda Fu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11967896/publications.pdf

Version: 2024-02-01

46	1,039	566801 15	433756 31
papers	citations	h-index	g-index

46	46	46	1574
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. JAMA Oncology, 2017, 3, 1692.	3.4	179
2	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Annals of Internal Medicine, 2015, 163, 127-134.	2.0	162
3	Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care, 2016, 39, 1241-1249.	4.3	154
4	Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies. Journal of the American Statistical Association, 2018, 113, 1-13.	1.8	66
5	Evaluating and utilizing probability of study success in clinical development. Clinical Trials, 2013, 10, 407-413.	0.7	44
6	Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies. Statistics in Medicine, 2016, 35, 3285-3302.	0.8	37
7	Detecting outlying trials in network metaâ€analysis. Statistics in Medicine, 2015, 34, 2695-2707.	0.8	34
8	Bayesian Adaptive Dose-Finding Studies with Delayed Responses. Journal of Biopharmaceutical Statistics, 2010, 20, 1055-1070.	0.4	28
9	Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis. Current Medical Research and Opinion, 2014, 30, 1787-1793.	0.9	28
10	Incorporation of individualâ€patient data in network metaâ€analysis for multiple continuous endpoints, with application to diabetes treatment. Statistics in Medicine, 2015, 34, 2794-2819.	0.8	27
11	Guidance on the implementation and reporting of a drug safety Bayesian network metaâ€analysis. Pharmaceutical Statistics, 2014, 13, 55-70.	0.7	24
12	Multi-Armed Angle-Based Direct Learning for Estimating Optimal Individualized Treatment Rules With Various Outcomes. Journal of the American Statistical Association, 2020, 115, 678-691.	1.8	23
13	Joint modeling of progressionâ€free survival and overall survival by a Bayesian normal induced copula estimation model. Statistics in Medicine, 2013, 32, 240-254.	0.8	19
14	Estimating Individualized Treatment Rules for Ordinal Treatments. Biometrics, 2018, 74, 924-933.	0.8	17
15	A General Framework for Treatment Effect Estimators Considering Patient Adherence. Statistics in Biopharmaceutical Research, 2020, 12, 1-18.	0.6	17
16	Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database. Clinical Therapeutics, 2017, 39, 1790-1798.e7.	1.1	16
17	Bayesian indirect and mixed treatment comparisons across longitudinal time points. Statistics in Medicine, 2013, 32, 2613-2628.	0.8	15
18	An Algorithm for Generating Individualized Treatment Decision Trees and Random Forests. Journal of Computational and Graphical Statistics, 2018, 27, 849-860.	0.9	13

#	Article	IF	Citations
19	Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications. Diabetes Care, 2016, 39, S219-S227.	4.3	10
20	Power and Commensurate Priors for Synthesizing Aggregate and Individual Patient Level Data in Network Meta-Analysis. Journal of the Royal Statistical Society Series C: Applied Statistics, 2018, 67, 1047-1069.	0.5	10
21	Quantifying the totality of treatment effect with multiple eventâ€time observations in the presence of a terminal event from a comparative clinical study. Statistics in Medicine, 2018, 37, 3589-3598.	0.8	10
22	Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis. Diabetes Therapy, 2015, 6, 317-328.	1.2	9
23	High-dimensional pseudo-logistic regression and classification with applications to gene expression data. Computational Statistics and Data Analysis, 2007, 52, 452-470.	0.7	8
24	Estimating individualized optimal combination therapies through outcome weighted deep learning algorithms. Statistics in Medicine, 2018, 37, 3869-3886.	0.8	8
25	Multicategory Outcome Weighted Margin-based Learning for Estimating Individualized Treatment Rules. Statistica Sinica, 2020, 30, 1857-1879.	0.2	7
26	Identifying Potential Adverse Events Dose-Response Relationships Via Bayesian Indirect and Mixed Treatment Comparison Models. Journal of Biopharmaceutical Statistics, 2013, 23, 26-42.	0.4	6
27	Ease of Use of Two Reusable, Half-Unit Increment Dosing Insulin Pens by Adult Caregivers of Children with Type 1 Diabetes: A Randomized, Crossover Comparison. Journal of Diabetes Science and Technology, 2013, 7, 582-583.	1.3	6
28	Hypoglycemic events analysis via recurrent time-to-event (HEART) models. Journal of Biopharmaceutical Statistics, 2016, 26, 280-298.	0.4	6
29	Multicategory Angle-Based Learning for Estimating Optimal Dynamic Treatment Regimes With Censored Data. Journal of the American Statistical Association, 2022, 117, 1438-1451.	1.8	6
30	Risk controlled decision trees and random forests forÂprecision Medicine. Statistics in Medicine, 2022, 41, 719-735.	0.8	6
31	Bayesian Optimal Adaptive Designs for Delayed-Response Dose-Finding Studies. Journal of Biopharmaceutical Statistics, 2011, 21, 888-901.	0.4	5
32	A randomized, cross-over comparison of preference between two reusable insulin pen devices in pen-naÃ¯ve adults with diabetes. Current Medical Research and Opinion, 2013, 29, 465-473.	0.9	5
33	Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241â€“1249. Diabetes Care, 2016, 39, e199-e200.	4.3	5
34	Crossover design and its application in lateâ€phase diabetes studies. Journal of Diabetes, 2016, 8, 610-618.	0.8	5
35	Bayesian isotonic regression doseâ€“response model. Journal of Biopharmaceutical Statistics, 2017, 27, 824-833.	0.4	5
36	A Bayesian approach to the statistical analysis of device preference studies. Pharmaceutical Statistics, 2012, 11, 149-156.	0.7	4

#	Article	IF	Citations
37	Estimate variable importance for recurrent event outcomes with an application to identify hypoglycemia risk factors. Statistics in Medicine, 2015, 34, 2743-2754.	0.8	3
38	Modeling the impact of preplanned dose titration on delayed response. Journal of Biopharmaceutical Statistics, 2019, 29, 287-305.	0.4	3
39	Masking effects on linear regression in multi-class classification. Statistics and Probability Letters, 2006, 76, 1800-1807.	0.4	2
40	Trifluridine/tipiracil in metastatic gastric cancer. Lancet Oncology, The, 2019, 20, e8.	5.1	2
41	Statistical Inference on the Estimators of the Adherer Average Causal Effect. Statistics in Biopharmaceutical Research, 2022, 14, 392-395.	0.6	2
42	Bayesian Adaptive D-Optimal Design with Delayed Responses. Journal of Biopharmaceutical Statistics, 2013, 23, 559-568.	0.4	1
43	Quantile regression modeling of latent trajectory features with longitudinal data. Journal of Applied Statistics, 2019, 46, 2884-2904.	0.6	1
44	Estimating individualized treatment rules for treatments with hierarchical structure. Electronic Journal of Statistics, 2022, 16, .	0.4	1
45	Analysis of recurrent hypoglycemic events. Journal of Biopharmaceutical Statistics, 2021, 31, 5-13.	0.4	0
46	Near-optimal Individualized Treatment Recommendations. Journal of Machine Learning Research, 2020, 21, .	62.4	0